{"id":"W2289712604","doi":"10.1016/s0140-6736(16)00561-4","title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3714,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; Genentech","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Population; Chemotherapy; Cancer; Progressive disease; Cohort; Urology; Immunotherapy; Bladder cancer; Pembrolizumab; Urothelial carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}